Monday 2 January 2012
Anti-interleukin-6 agents are a recent class of therapeutics.
Interleukin-6 is relevant to many inflammatory diseases and many cancers. Hence anti-IL-6 agents have been sought.
In clinical trials
- esilimomab for some cancers
- CPSI-2364, CDP6038.